Endothelial malfunctions in patients with diabetes are known to result in vascular diseases, and endothelial progenitor cells (EPCs) are indispensable for the functional preservation of the vascular endothelium. MicroRNA-31 (miR-31) has been found to be able to modulate the differentiation of stem cells. However, it is still unclear how miR-31 functions in diabetic EPCs. The aim of this study was to investigate how miR-31 regulates diabetic EPC function. In the current study, miR-31 expression was compared between normal and diabetic EPCs. Satb2 was recognized as a functionally related target of miR-31 in EPCs according to computational prediction. We also explored the role of miR-31 in terms of its anti-apoptotic effects. A remarkable elevation in miR-31 expression was found in diabetic EPCs, and this elevated expression resulted in suppressed cell proliferation under high glucose. It was also found that miR-31 targets Satb2, leading to the anti-apoptotic effect and maintenance of the functions of EPCs. Furthermore, knockdown of Satb2 exhibited an inhibitory effect on proliferation and migration of EPCs in both healthy and diabetic subjects, which showed the same trend as miR-31 overexpression. Conversely, overexpression of Satb2 showed the opposite effect. Moreover, overexpression of Satb2 attenuated the miR-31-induced migration and colony-forming ability reduction and apoptosis induction of EPCs in both healthy and diabetic subjects. In diabetic EPCs, elevated glucose level was found to up-regulate miR-31 expression, which in turn enhanced the malfunction and death of EPCs. In conclusion, our results indicate that up-regulation of miR-31 may underlie endothelial dysfunction in diabetes by targeting Satb2.
Introduction
As an essential risk factor of diverse cardiovascular diseases (CVD), diabetes mellitus (DM) is related to a series of vascular complications [1] . Endothelial malfunction leads to various vascular diseases in patients with diabetes, and endothelial progenitor cells (EPCs) are indispensable for proper functioning of vascular endothelium [2, 3] . Prior to their differentiation into mature endothelium, EPCs from bone marrow move to the ischemic regions of injured vessels, where they participate in the functional recovery of the endothelium [4, 5] . Hyperglycemia, the main contributor to the vascular complications in patients with diabetes, is related to endothelial malfunction [6] . DM is closely linked to lowered concentration of EPCs in circulation as well as malfunction of EPCs, particularly in terms of reduced migration, adhesion and proliferation [7, 8] . Previous studies have proved that DM suppresses the amount of circulating EPCs and negatively regulates its functional capacity of EPCs [9, 10] . Therefore, in order to explore innovative approaches to treat DM complications, it is essential to reveal the mechanisms of EPC malfunction in DM.
MicroRNAs (miRNAs) are noncoding small RNAs which modulate the expression of genes via either mRNA degradation or translational inhibition [11] . MiRNAs participate in the modulation of diverse biological events, such as maintenance of bone homeostasis, inflammation, differentiation of bone-forming stem cells, and infection [12] [13] [14] . Recent studies revealed that miR-31 was able to modulate the differentiation of bone-forming stem cells into mesenchymal and fat tissues [15, 16] . Satb2 is a transcription factor related to the nuclear matrix and is also an epigenetic modulator. It is highly conserved across various taxa and is indispensable for the differentiation of osteoblasts, craniofacial patterning, and generation and progression of neurons [17] [18] [19] . Nevertheless, our current understanding of miR-31 function in EPCs of diabetic individuals is yet incomplete.
In the present study, we investigated the relationship between miR-31 and EPC malfunction. The study enriches our understanding about the role of miRNAs in EPC dysfunction. Furthermore, we also suggested some novel approaches to promote viability of EPCs in order to manage the complications in DM.
Materials and Methods

Study participants
The patients suffering from Type II diabetes mellitus (n = 25) were recruited from the Tenth People's Hospital of Tongji University (Shanghai, China). Peripheral blood (20 ml) was obtained from each participant prior to treatment. Written informed consent was obtained from all the study participants. Twenty-five healthy individuals admitted to the same hospital only for preventive examinations were enrolled as controls. The study protocol was approved by the Research Ethics Committee of the Tenth People's Hospital of Tongji University.
Isolation and culture of EPCs
Blood samples (20 ml) were mixed with 1 ml heparin (Sigma, St Louis, USA), and mononuclear cells were isolated by density gradient centrifugation using Ficoll-Isopaque Plus (GE Healthcare Life Sciences, Piscataway Township, USA) within 2 h of sampling. Magnetic microbeads coupled with CD133 Microbead Kit (Miltenyi Biotech, Cambridge, USA) were used for the separation of CD133 + cells from the mononuclear cells isolated from blood as instructed. DMEM/F12 medium (Gibco, Gaithersburgh, USA) supplemented with 2% fetal bovine serum (FBS; Gibco), 10 μg/l bFGF (Sigma), 10 μg/l EGF (Sigma), 10 μg/l VEGF (Sigma), and 2 μg/l IGF (Sigma) was used to resuspend CD133 + cells. After 3 days of incubation at 37°C in 5% CO 2 , dead cells were washed away with PBS and new medium was added, and then cell culture was continued until the seventh day.
Identification of EPCs
Lectin conjugated to fluorescein isothiocyanate of Ulex europaeus agglutinin 1 (FITC-UEA-1; Sigma) and Dil-ac-LDL (Cell Applications, San Diego, USA) was used for incubation of EPCs after 7 days of culture. FITC-UEA-1 binding and Dil-ac-LDL participation were examined by confocal microscopy (Zeiss, Oberkochen, Germany 
Lentiviral generation, packaging, and transduction
Nucleotide sequences of miR-31 and Satb2 were amplified by PCR using human genomic DNA as template and primers were listed in Table 1 . Subsequently, the amplified regions of miR-31 and Satb2 were cloned into pLKO.1-puro and pCDH-EF1-MCS-T2A-puro vectors, respectively. Sanger sequencing was carried out to verify these constructs. For lentiviral generation, 293T cells were co-transfected with the above-mentioned constructs and the pMD2G packaging agent-psPAX2 (Addgene, Cambridge, USA) with Lipofectamine 2000 (Invitrogen, Carlsbad, USA) according to the manufacturer's instructions. Culture medium was replaced every 6 h, and the supernatant was obtained after 48 h. EPCs were seeded in 6-well plates at a density of 5 × 10 5 cells/well. Transfection was carried out with the help of various lentiviral vectors at the multiplicity of infection of 10. After 2 days of infection, cells were selected and then cloned with the help of the 1-week culture supplemented with puromycin (2 μg/ml).
Luciferase reporter assay
The Satb2 3′-UTR was amplified from human cDNA library by RT-PCR as wild-type Satb2 (Satb2-WT). Satb2 mutant (Satb2-MUT) containing the desired mutation was prepared by site-directed mutagenesis. The inserts (Satb2-WT or Satb2-MUT) were cloned downstream to the luciferase reporter gene in the pMIR-report vector (Life Technologies, Carlsbad, USA). The EPCs seeded in 96-well plate were co-transfected with lenti-miR-control or lenti-miR-31 and Satb2-MUT or Satb2-WT using Lipofectamine 2000 according to the manufacturer's instructions. After transfection for 24 h, the medium was aspirated and discarded, and then cells were washed with PBS. A total of 100 μl of lysis buffer (Sigma) was used to lyze the cells. DualGlo Luciferase Assay System (Promega, Durham, USA) was used to examine the luciferase activity. 
Cell transfection
One day prior to transfection, cells were seeded in 24-well plates at a density of 5 × 10 4 cells/well. When EPCs were grown to 30%-40% confluence, cells were transfected with control siRNA (5′-UAAGG CUAUGAAGAGAUAC-3′) or Satb2-siRNA (5′-CCAAACACACCA UCAUCAAGU-3′) (Santa Cruz Biotechnology, Santa Cruz, USA) using Lipofectamine 2000 according to the manufacturer's instructions. Medium was replaced with fresh medium after 6 h of transfection, and the cells were cultured for additional 24 h before being used for further analysis. In order to inhibit miR-31, EPCs were also transfected with a miR-31 inhibitor (anti-miR-31, 5′-CAGCUAUG CCAGCAUCUUGCCU-3′) and a anti-miR negative control (5′-CAG UACUUUUGUGUAGUACAA-3′). Every transfection required 200 nM miRNA and 50 nM RNA duplex except stated otherwise.
RNA extraction and real-time PCR
Trizol reagent (Qiagen, Frederick, USA) was utilized to extract total RNA from EPCs. PrimeScript RRT Master Mix Perfect Real Time (Takara, Dalian, China) was used for reverse transcription. Amplification was carried out using the PCR kit (Qiagen). MiR-31 expression was examined by TaqMan qPCR, and primers used were listed in 
Western Blot analysis
EPCs were collected before supplementation with lysis buffer (300 μl) including 1× proteasome suppressor (Sigma) and PMSF (1 mM; Sigma). The protein samples (20 μg) were electrophoresed on 10% SDS-PAGE before transferring onto PVDF membranes. The desired protein bands were detected using primary antibodies against β-actin and Satb2 (Santa Cruz Biotechnology).
Apoptosis assay
Nuclear staining with the help of Hoechst 33,258 (Invitrogen) was used to evaluate of cell death. A minimum of 300 cells was analyzed each time. Annexin V/propidium iodide (PI) staining was used with the help of annexin-Alexa 488 (Invitrogen) and PI followed by flow cytometry analysis.
Colony-forming assay
Briefly, separated EPCs were resuspended in endothelial growth media. Six-well plates coated with fibronectin were used to seed EPCs (5 × 10 6 ). Cells without adhesion were selected and seeded again into 24-well plates (1 × 10 6 cells/well) coated with fibronectin after two days. Colony-forming units (CFUs) were randomly evaluated in four wells on Day 5. Only CFUs containing a central core of round cells along with outspreading spindle-like cells were considered as colonies.
Migration assay
The modified Boyden chamber (Neuro Probe, Gaitherburgh, USA) was used for cell migration assays. Briefly, endothelial basal medium (EBM) without serum was used to resuspend EPCs (4 × 10 4 cells).
Then cells were seeded in the upper part of the chamber. EBM containing VEGF (50 ng/ml) was provided in these chambers. Incubation lasted for 24 h at 37°C. After the bottom of the filter was washed with PBS, cells were fixed with 4% paraformaldehyde. Cells were then stained with hematoxylin and evaluated randomly in three highpower fields (HPF) in each well.
Statistical analysis
Results were presented as the mean ± standard deviation (SD) from five experiments. Prism V statistical software was used for analysis. Student's t-test and two-way ANOVA were used to compare the experimental groups. P < 0.05 was considered as statistically significant.
Results
Characterization of EPCs and miR-31 expression in EPCs derived from diabetic subjects
EPCs were isolated from blood specimens of the study participants.
Clinical findings of the patients in the initial stage are listed in the Table 2 . EPCs formed clusters after four days of culture. Spindlelike cells appeared at marginal clusters after 7 days; these cells grew larger gradually and started to form a structure similar to cobblestones on the 10th day. In order to explore how miR-31 affected EPCs, miR-31 level was examined by qRT-PCR. MiR-31 expression was remarkably enhanced in EPCs of diabetic participants than in those of healthy controls (P < 0.05; Fig. 1A ). In addition, the relative expression level of miR-31 was 2.47 ± 0.12 in EPCs cultured in media with high level of glucose (25 mM), while it was 1.03 ± 0.04 in the control group, indicating a noticeable 2.4-fold increase in miR-31 expression at elevated glucose concentration (P < 0.05; Fig. 1B ).
Proliferation and apoptosis of EPCs under high glucose concentration
Proliferation (indicated by the proportion of Day 4) was assessed in EPCs derived from diabetic and healthy subjects with or without high concentration of glucose on Day 8, 12, and 16 by the MTS assay ( Fig. 2A) . The results suggested that proliferation of EPCs was retarded under high glucose concentration. Subsequently, apoptotic cell death was investigated in the presence of high level of glucose.
Rates of apoptosis among EPCs under high concentration of glucose were estimated at regular time intervals. It was found that high concentration of glucose triggered apoptosis in a time-dependent manner (Fig. 2B) . Nuclear staining assay was also used to detect the apoptotic cells. Under high concentration of glucose, apoptosis was enhanced in a time-dependent manner (Fig. 2C) . Our results indicate 
MiR-31 suppresses EPC function
In order to explore how miR-31 affects the function of EPCs, EPCs derived from healthy or diabetic subjects were transfected with empty vector (control), lenti-miR-31 (overexpressing miR-31) or anti-miR-31 (miR-31 inhibitor). After different treatments, we confirmed that miR-31 was significantly decreased in both diabetic EPCs and healthy EPCs transfected with miR-31 inhibitor. MiR-31 was increased in the lentimiR-31 group of EPCs derived from healthy subjects to mimic those derived from diabetic subjects (P < 0.05 vs. control; Fig. 3A ). As shown in the Fig. 3B -D, miR-31 down-regulation considerably enhanced the migration ability of EPCs derived from both diabetic and healthy subjects. Furthermore, miR-31 down-regulation not only enhanced colony-forming ability but also suppressed apoptosis of EPCs from diabetic subjects (P < 0.05 vs. control); and miR-31 upregulation remarkably suppressed migration and colony-forming abilities and promoted cell death of EPCs (P < 0.05 vs. control).
MiR-31 targets Satb2 in EPCs
Computational target prediction was used to identify functional miR-31 targets in EPCs derived from diabetic subjects. It was found that miR-31 could target Satb2 which harbors a potential miR-31 binding site (Fig. 4A) . To verify this prediction, a sequence of Satb2 3′-UTR including miR-31 binding site was cloned into the luciferase reporter pMIR-report (Satb2-WT), which was located downstream to the reporter. A pattern of miR-31 binding site after mutation (Satb2-MUT) was also constructed. EPCs were co-transfected with miR-31 or miR-control and Satb2-MUT or Satb2-WT construct. Overexpression of miR-31 substantially suppressed luciferase activity in EPCs with Satb2-WT; however, the luciferase activity was not influenced by miR-control (Fig. 4B) . In the meantime, suppression of luciferase capability modulated by miR-31 was attenuated by the mutant putative binding site of the Satb2-MUT (Fig. 4B) . Western blot analysis revealed that Satb2 expression was suppressed more in EPCs of diabetic subjects than in those of healthy controls (Fig. 4C) .
To confirm this finding, miR-31 expression was examined in EPCs derived from healthy subjects. These EPCs were transfected with lentivirus containing miR-31 or miR-control. It was found that miR-31 expression was noticeably enhanced in the cells transfected with miR-31 (P < 0.05; Fig. 4D ), indicating that overexpression of miR-31 was successful in the transfected EPCs. Furthermore, increased expression of miR-31 in EPCs remarkably suppressed the expression of Satb2 when compared to that in the miR-control group (Fig. 4D) .
These findings indicate that miR-31 targets Satb2, which could modulate miR-31 activity in EPCs. , and 72 h. Nuclear fragmentation assay was performed for the assessment of cell death. Results in (B,C) were expressed as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
Satb2 is required for miR-31-induced EPC dysfunction
We investigated the Satb2-mediated influence of miR-31 on EPC function and found that Satb2 protein expression was reduced by overexpression of miR-31 or by Satb2-siRNA knockdown in EPCs derived from healthy subjects; however, it was increased by miR-31 down-regulation or increased transcription of Satb2 (Fig. 5A ). Furthermore, Satb2 protein level was decreased by miR-31 overexpression or Satb2-siRNA in EPCs from diabetic subjects, while Satb2 protein expression was increased by anti-miR-31 (Fig. 5B) . Moreover, Satb2 upregulation significantly enhanced the migration ability of EPCs derived Results were expressed as the mean ± SD of three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001.
from both diabetic and healthy subjects; the up-regulation enhanced colony-forming ability and suppressed cell death of EPCs from diabetic subjects (P < 0.05 vs. control; Fig. 5C-E) . Satb2 down-regulation noticeably suppressed colony-forming and migration abilities but enhanced cell death of EPCs derived from both diabetic and healthy subjects (P < 0.05 vs. control; Fig. 5F -H). These findings indicate that Satb2 is necessary for miR-31-induced EPC dysfunction.
MiR-31 affects EPC function through Satb2
To explore the effect of Satb2 and miR-31 on EPC dysfunction, the migration and colony-forming abilities and the apoptosis of EPCs were investigated after the treatment. It was found that overexpression of miR-31 decreased migration and colony-forming abilities and increased apoptosis of EPCs (P < 0.05 vs. control; Fig. 6A-C) . Moreover, overexpressed Satb2 attenuated the miR-31-induced reduction in migration and colony-forming abilities and the miR-31-induced increase in apoptosis of EPCs (P < 0.05 vs. control; Fig. 6A-C) . These findings suggest that miR-31 may affect EPC function through Satb2.
Discussion
Endothelium dysfunction is an important complication of DM. Patients with diabetes have 2-to 4-fold higher risk of CVD than healthy individuals [20, 21] . People at pre-diabetic stage, which includes reduced tolerance to glucose and suppressed fasting glucose, are more vulnerable to cardiovascular complications [22] . Endothelial dysfunction is considered as the initiation of atherosclerosis, which is because of high levels of serum lipid and oxidative stress of vessels [23] . Nevertheless, understanding of the modulation of upstream stimulation under high glucose is yet inadequate.
The function of miRNA has been investigated in diverse pathological reactions such as pathogenesis modulated by EPCs of DM complications [12, 24] . Consistent with previous studies, remarkable up-regulation of miR-31 was observed in the present study, indicating that elevated miR-31 could suppress EPC functions in diabetic subjects [25, 26] . MiR-31 is expressed in a variety of cells and modulates diverse reactions by targeting various proteins [27] . In order to confirm how elevated concentration of glucose affects miR-31 expression, EPCs derived from healthy subjects were grown under high glucose concentration to mimic the microenvironment of DM. EPCs from healthy subjects demonstrated remarkably enhanced proliferation than those from diabetic subjects or those under high concentration of glucose. We also found that up-regulation of miR-31 triggered apoptosis in EPCs. These findings indicate a potential link between EPC death and miR-31 up-regulation.
A few databases were used to search potential targets of miR-31, revealing that it could target Satb2 in EPCs. Thus, Satb2 could explain the mechanism of how miR-31 affects EPC function in diabetic endothelial injury. We speculated that reduced proliferation of EPCs of diabetic subjects could be attributed to miR-31 upregulation, which was triggered by elevated glucose level. In order to confirm this hypothesis, luciferase assay was carried out, which aims to prove that miR-31 directly bind with the complementary regions of Satb2 3′-UTR and that overexpression of miR-31 in EPCs substantially can reduce transcription and translation of Satb2. We demonstrated that EPC functions were suppressed in diabetic subjects in comparison to those in healthy subjects, and this suppression in EPC function may be related to miR-31 down-regulation and its influence on Satb2. The inhibition of miR-31 in EPCs of healthy subjects has a detrimental effect on EPC function, as anti-miR-31 significantly reduces migration and colony-forming abilities and increases apoptosis in EPCs, when compared to those of the negative control. These findings indicate that miR-31 maintains normal functions of EPCs by targeting Satb2.
Satb2 plays substantial roles in cancer development and prognosis, central nervous system (CNS) development, and immune regulation. Various reports on the involvement of Satb2 in different cancers have shown its cancer specific effects. Satb2 is a marker of posterior parenchymal differentiation of colorectal adenocarcinomas and neuroendocrine tumors. Moreover, Satb2 is highly expressed in osteosarcoma cells and has been used as a sensitive marker of bone malignancy. However, it has been suggested that Satb2 acts as tumor suppressor [17, 18] . However, no case with documented Satb2 haploinsufficiency has been reported with malignancies. Thus, the precise role of Satb2 in cancer remains unclear.
In order to confirm the outcome of gain-of-function, we further investigated whether Satb2 modulates the role of miR-31 in EPCs of diabetic subjects. In EPCs transfected with Satb2-siRNA or lenti-miR-31, transcription and translation of Satb2 was impaired. Nevertheless, migration and colony-forming abilities were enhanced, while apoptosis was suppressed. Our results indicated that miR-31 could negatively regulate Satb2 expression through directly targeting the 3′-UTR of Satb2 mRNA and that miR-31 could affect EPC survival. As Satb2 is a highly conserved transcription factor and is structurally homologous to homeobox, PDZ, and CUT domains, it participates in transcription and chromatin remodeling. It has previously been reported that Satb2 is essential to CNS development, differentiation of osteoblasts, and craniofacial patterning [28] [29] [30] . Satb2 down-regulation has been proved to be responsible for the limited survival of GC patients [31] , and overexpression of Satb2 could inhibit the proliferation and migration of GC cells [32] . Furthermore, knockdown of Satb2 could noticeably suppress the invasion and migration of osteosarcoma cells [33] . In the present study, down-regulation of Satb2 was found to regulate the activities of EPCs derived from diabetic subjects.
In conclusion, we demonstrated the up-regulation of miR-31 in EPCs from patients with diabetes, and found that miR-31 is essential for the suppression of EPC function, most probably through directly targeting Satb2. These findings indicate that miR-31 up-regulation may be a target for developing potential therapeutic agents and better management of DM in the future.
